Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Market Makers on radar! LONG confirmed! More and More VOLUME! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
Market Makers decide! It's going up! Purchase offers confirmed! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
Market Makers decide! It's going up! Purchase offers confirmed! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
$GSFI News! Green Stream Holdings Prepares for Major 2021 Growth with Appointment of New CEO James C. DiPrima
Newsfile Corp.
Newsfile Corp
Malibu, California--(Newsfile Corp. - January 28, 2021) - Green Stream Holdings Inc. (OTC Pink: GSFI) ("the Company") ("Green Stream") (http://www.GreenRainSolar.com), an emerging leader in the solar utility and finance space, is pleased to announce the appointment of Mr. James C. DiPrima as the new corporate Chief Executive Officer.
Green Stream Holdings
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/73027_0e518535b4f65845_002full.jpg
The global solar energy market is projected to grow at an average of 20% per year, surpassing $220 billion by 2026, according to Allied Market Research.
Mr. James C. DiPrima has a Bachelor of Science in Business Administration from Creighton University, Omaha, Nebraska. His career includes 40 years of finance and accounting in both the public and private sectors beginning his career at Deloitte & Touche. He has held various positions with start-up companies, was comptroller of a manufacturing company, founded and operated an accounting and tax consulting firm focused on medical practice management and investment and tax planning. He has served as chief executive officer of MBD Midwest, a holding company for national pack and ship franchises where he managed the development of retail outlets in multiple states. Mr. DiPrima was founder and President of a construction company providing various services to the United States Postal Services.
Mr. DiPrima has been working in various positions with publicly traded companies since 1995. His accomplishments included guiding several companies through the reverse merger process, raising capital and consulting on various mezzanine financings. Most recently he has served as CEO of PAO Group, Inc. a publicly traded holdings company dedicated to operating businesses within the medical cannabis sector focused on medical research and the development of treatments derived from its patented cannabis extraction process. He has also served as CFO for Solar Integrated Roofing, Inc. a public traded company that provides residential solar energy solutions in southern California. Additionally, Mr. DiPrima provides various financial services to micro-cap publicly traded companies on a contract basis.
"Green Stream's recent press highlights the move to New York City as the solar utility services ramp in 2021. We are excited to bring Mr. James C. DiPrima on board to take the helm. His intimate knowledge of the public market space along with strong solar industry experience makes him the perfect candidate to fulfill our business plans moving forward," stated outgoing CEO Eric Fain.
"I am eager to expand the already existing opportunities that Green Stream's innovative solutions will provide to commercial solar energy markets on the East Coast. There is unlimited potential in this segment of the renewable energy space," commented James C. DePrima, CEO.
GSFI - Strategic Moves
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/73027_0e518535b4f65845_003full.jpg
https://www.otcmarkets.com/stock/GSFI/news/story?e&id=1795847
$GSFI News! Green Stream Holdings Prepares for Major 2021 Growth with Appointment of New CEO James C. DiPrima
Newsfile Corp.
Newsfile Corp
Malibu, California--(Newsfile Corp. - January 28, 2021) - Green Stream Holdings Inc. (OTC Pink: GSFI) ("the Company") ("Green Stream") (http://www.GreenRainSolar.com), an emerging leader in the solar utility and finance space, is pleased to announce the appointment of Mr. James C. DiPrima as the new corporate Chief Executive Officer.
Green Stream Holdings
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/73027_0e518535b4f65845_002full.jpg
The global solar energy market is projected to grow at an average of 20% per year, surpassing $220 billion by 2026, according to Allied Market Research.
Mr. James C. DiPrima has a Bachelor of Science in Business Administration from Creighton University, Omaha, Nebraska. His career includes 40 years of finance and accounting in both the public and private sectors beginning his career at Deloitte & Touche. He has held various positions with start-up companies, was comptroller of a manufacturing company, founded and operated an accounting and tax consulting firm focused on medical practice management and investment and tax planning. He has served as chief executive officer of MBD Midwest, a holding company for national pack and ship franchises where he managed the development of retail outlets in multiple states. Mr. DiPrima was founder and President of a construction company providing various services to the United States Postal Services.
Mr. DiPrima has been working in various positions with publicly traded companies since 1995. His accomplishments included guiding several companies through the reverse merger process, raising capital and consulting on various mezzanine financings. Most recently he has served as CEO of PAO Group, Inc. a publicly traded holdings company dedicated to operating businesses within the medical cannabis sector focused on medical research and the development of treatments derived from its patented cannabis extraction process. He has also served as CFO for Solar Integrated Roofing, Inc. a public traded company that provides residential solar energy solutions in southern California. Additionally, Mr. DiPrima provides various financial services to micro-cap publicly traded companies on a contract basis.
"Green Stream's recent press highlights the move to New York City as the solar utility services ramp in 2021. We are excited to bring Mr. James C. DiPrima on board to take the helm. His intimate knowledge of the public market space along with strong solar industry experience makes him the perfect candidate to fulfill our business plans moving forward," stated outgoing CEO Eric Fain.
"I am eager to expand the already existing opportunities that Green Stream's innovative solutions will provide to commercial solar energy markets on the East Coast. There is unlimited potential in this segment of the renewable energy space," commented James C. DePrima, CEO.
GSFI - Strategic Moves
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/73027_0e518535b4f65845_003full.jpg
https://www.otcmarkets.com/stock/GSFI/news/story?e&id=1795847
GM all! $MCET LONG!
Nice day today!
$MCET Please Read! Great Multicell Technologies Article from Journal of Nanobiotechnology!
Treatment of breast cancer with autophagy inhibitory microRNAs carried by AGO2-conjugated nanoparticles
28 April 2020
Materials and methods
... Ethylenediaminetetraacetic acid (EDTA) disodium salt was purchased from Multicell (U.S.A.)...
https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-020-00615-4
https://jnanobiotechnology.biomedcentral.com/track/pdf/10.1186/s12951-020-00615-4.pdf
$MCET Please Read! Great Multicell Technologies Article from Journal of Nanobiotechnology!
Treatment of breast cancer with autophagy inhibitory microRNAs carried by AGO2-conjugated nanoparticles
28 April 2020
Materials and methods
... Ethylenediaminetetraacetic acid (EDTA) disodium salt was purchased from Multicell (U.S.A.)...
https://jnanobiotechnology.biomedcentral.com/articles/10.1186/s12951-020-00615-4
https://jnanobiotechnology.biomedcentral.com/track/pdf/10.1186/s12951-020-00615-4.pdf
$MCET Seven Patents Active: Multicell Technologies, Rhode Island Hospital and Xenotech ( SEKISUI XenoTech )
One Patent Multicell Technologies Receives Stem Cell Patent Active!
Inventor: Ronald A. Faris
Current Assignee: Rhode Island Hospital
US7935528 B2
Application granted
Status Active
2022-10-21 Adjusted expiration
https://patents.google.com/patent/US7935528B2/en?oq=7%2c935%2c528
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
https://www.patentdocs.org/2011/07/patent-profile-multicell-technologies-receives-stem-cell-patent.html
Six Fa2N-4 Multicell Technologies / Xenotech Patents Active!
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
US 7566567 B2 Immortalized hepatocytes
Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US7566567B2/en?oq=7%2c566%2c567
Inventor: Jin Liu, Ronald A. Faris
Current Assignee: Multicell Technologies
EP 1704227 B1 IMMORTALIZED HEPATOCYTES
Doc Type: Granted Patent
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227B1/en?oq=EP1704227B1
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A4 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A4/en?oq=EP1704227A4
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A1 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A1/en?oq=EP1704227A1
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
DE 602004025380 D1 IMMORTALISIERTE HEPATOZYTEN
Doc Type: Granted Patent
Status Active
2024-10-08 Anticipated expiration
https://patents.google.com/patent/DE602004025380D1/en?oq=DE602004025380
Inventor: Jin LiuRonald Farie
Current Assignee: Multicell Technologies Inc
US20070004039 A1 Immortalized hepatocytes
2009-07-28 Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US20070004039A1/en?oq=US20070004039A1
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-28
$MCET Seven Patents Active: Multicell Technologies, Rhode Island Hospital and Xenotech ( SEKISUI XenoTech )
One Patent Multicell Technologies Receives Stem Cell Patent Active!
Inventor: Ronald A. Faris
Current Assignee: Rhode Island Hospital
US7935528 B2
Application granted
Status Active
2022-10-21 Adjusted expiration
https://patents.google.com/patent/US7935528B2/en?oq=7%2c935%2c528
The invention provides a primary liver stem cell and a cell doublet consisting of a hepatocyte and the stem cell, both of which are derived from normal liver tissue. Methods of isolating the cells, genetically altering the cells, and using the cells for transplantation are also within the invention.
https://www.patentdocs.org/2011/07/patent-profile-multicell-technologies-receives-stem-cell-patent.html
Six Fa2N-4 Multicell Technologies / Xenotech Patents Active!
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
US 7566567 B2 Immortalized hepatocytes
Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US7566567B2/en?oq=7%2c566%2c567
Inventor: Jin Liu, Ronald A. Faris
Current Assignee: Multicell Technologies
EP 1704227 B1 IMMORTALIZED HEPATOCYTES
Doc Type: Granted Patent
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227B1/en?oq=EP1704227B1
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A4 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A4/en?oq=EP1704227A4
Inventor: Jin Liu, Ronald A Faris
Current Assignee: Multicell Technologies Inc
EP1704227 A1 IMMORTALIZED HEPATOCYTES
Application granted
Status Active
2024-10-07 Anticipated expiration
https://patents.google.com/patent/EP1704227A1/en?oq=EP1704227A1
Inventor: Jin LiuRonald A. Faris
Current Assignee: Multicell Technologies
DE 602004025380 D1 IMMORTALISIERTE HEPATOZYTEN
Doc Type: Granted Patent
Status Active
2024-10-08 Anticipated expiration
https://patents.google.com/patent/DE602004025380D1/en?oq=DE602004025380
Inventor: Jin LiuRonald Farie
Current Assignee: Multicell Technologies Inc
US20070004039 A1 Immortalized hepatocytes
2009-07-28 Application granted
Status Active
2025-01-13 Adjusted expiration
https://patents.google.com/patent/US20070004039A1/en?oq=US20070004039A1
Family timeline https://www.lens.org/lens/patent/167-627-709-236-287/family
Immortalized Hepatocytes https://www.lens.org/lens/patent/167-627-709-236-28
News! Green Stream Holdings Prepares for Major 2021 Growth with Appointment of New CEO James C. DiPrima
Newsfile Corp.
Newsfile Corp
Malibu, California--(Newsfile Corp. - January 28, 2021) - Green Stream Holdings Inc. (OTC Pink: GSFI) ("the Company") ("Green Stream") (http://www.GreenRainSolar.com), an emerging leader in the solar utility and finance space, is pleased to announce the appointment of Mr. James C. DiPrima as the new corporate Chief Executive Officer.
Green Stream Holdings
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/73027_0e518535b4f65845_002full.jpg
The global solar energy market is projected to grow at an average of 20% per year, surpassing $220 billion by 2026, according to Allied Market Research.
Mr. James C. DiPrima has a Bachelor of Science in Business Administration from Creighton University, Omaha, Nebraska. His career includes 40 years of finance and accounting in both the public and private sectors beginning his career at Deloitte & Touche. He has held various positions with start-up companies, was comptroller of a manufacturing company, founded and operated an accounting and tax consulting firm focused on medical practice management and investment and tax planning. He has served as chief executive officer of MBD Midwest, a holding company for national pack and ship franchises where he managed the development of retail outlets in multiple states. Mr. DiPrima was founder and President of a construction company providing various services to the United States Postal Services.
Mr. DiPrima has been working in various positions with publicly traded companies since 1995. His accomplishments included guiding several companies through the reverse merger process, raising capital and consulting on various mezzanine financings. Most recently he has served as CEO of PAO Group, Inc. a publicly traded holdings company dedicated to operating businesses within the medical cannabis sector focused on medical research and the development of treatments derived from its patented cannabis extraction process. He has also served as CFO for Solar Integrated Roofing, Inc. a public traded company that provides residential solar energy solutions in southern California. Additionally, Mr. DiPrima provides various financial services to micro-cap publicly traded companies on a contract basis.
"Green Stream's recent press highlights the move to New York City as the solar utility services ramp in 2021. We are excited to bring Mr. James C. DiPrima on board to take the helm. His intimate knowledge of the public market space along with strong solar industry experience makes him the perfect candidate to fulfill our business plans moving forward," stated outgoing CEO Eric Fain.
"I am eager to expand the already existing opportunities that Green Stream's innovative solutions will provide to commercial solar energy markets on the East Coast. There is unlimited potential in this segment of the renewable energy space," commented James C. DePrima, CEO.
GSFI - Strategic Moves
To view an enhanced version of this graphic, please visit:
https://orders.newsfilecorp.com/files/6720/73027_0e518535b4f65845_003full.jpg
https://www.otcmarkets.com/stock/GSFI/news/story?e&id=1795847
Looks like a controlled stop.
A type of repurchase of shares through monetary assets, based on income.
That can happen today, tomorrow or next week.
$MCET Multicell Technologies buys between 0.0008s-0.0009s. Look here >>>
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161183812
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161223308
$MCET Multicell Technologies buys between 0.0008s-0.0009s. Look here >>>
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161183812
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161223308
Multicell Technologies buys between 0.0008s-0.0009s.
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161183812
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161223308
And! Multicell Technologies has two active programs! Commercial and Government Entity NCAGE481X3 and COMMERCIAL AND GOVERNMENT ENTITY PROGRAM CAGE481X3
NCAGE CODE 481X3: NCAGE Code Registration Status A - Active record
MULTICELL TECHNOLOGIES, INC. Last Updated 2020-02-26 04:18:07
https://cage.report/NCAGE/481X3
Status Active CAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://cage.dla.mil/Search/Details?id=894402
NAICS Code 541711 – Research and Development in Biotechnology
https://classcodes.com/lookup/naics-code-541711/
Definition of NAICS Code 541711: This U.S. industry comprises establishments primarily engaged in conducting biotechnology research and experimental development. Biotechnology research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology may result in development of new biotechnology processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.
You can also download your own copy of the complete 2017 NAICS Classification Manual. The NAICS Manual is updated every five years. The 2017 copy will be applicable until a new edition is produced in 2022.
Illustrative Examples of NAICS 541711
What are some examples of this code? The bulleted items below are illustrative examples of this classification.
Recombinant DNA research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Cloning research and experimental development laboratories
Protein engineering research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Cross Reference Guide for Code 541711
What codes are similar to this classification that might be a more applicable code? The cross-reference guide below displays the codes for other similar industries. Please review to find the most applicable classification.
Conducting research and experimental development in the physical, engineering, and life sciences (except biotechnology)–are classified in U.S. Industry NAICS 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology);
Providing veterinary testing services–are classified in Industry NAICS 541940, Veterinary Services; Providing physical, chemical, or other analytical testing services (except medical or veterinary), such as acoustics or vibration testing, calibration testing, electrical and electronic testing, geotechnical testing, mechanical testing, nondestructive testing, or thermal testing–are classified in Industry NAICS 541380, Testing Laboratories;
Manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic use)–are classified in U.S. Industry NAICS 325414, Biological Product (except Diagnostic)
Manufacturing; and Manufacturing uncompounded medicinal chemicals and their derivatives (i.e., enzyme proteins and antibiotics for pharmaceutical use)–are classified in U.S. Industry NAICS 325411, Medicinal and Botanical Manufacturing.
Other Index Entries for NAICS 541711
The North American Industry Classification System contains multiple index entries that are each descriptive of the same code. The bulleted list below shows all applicable index entries (Current and former) that are associated with this classification. These index entries further elaborate on the scope of applicable industries that have already been defined at the top of this page.
Biotechnology research and development laboratories or service in botany
Biotechnology research and development laboratories or services
Biotechnology research and development laboratories or services in agriculture
Biotechnology research and development laboratories or services in bacteriology
Biotechnology research and development laboratories or services in biology
Biotechnology research and development laboratories or services in chemical sciences
Biotechnology research and development laboratories or services in entomology
Biotechnology research and development laboratories or services in environmental science
Biotechnology research and development laboratories or services in food science
Biotechnology research and development laboratories or services in genetics
Biotechnology research and development laboratories or services in health sciences
Biotechnology research and development laboratories or services in industrial research
Biotechnology research and development laboratories or services in the medical sciences
Biotechnology research and development laboratories or services in the physical sciences
Biotechnology research and development laboratories or services in the veterinary sciences
Cloning research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Protein engineering research and experimental development laboratories
Recombinant DNA research and experimental development laboratories
Suggested Insurance Conversion Table for NAICS Code 541711
Looking for an insurance classification other than the North American Industry Classification System? If a company falls within the industry defined on this page, then the class codes mentioned below may be applicable. Please note that the bulleted cross-reference guide below is not authoritative. Users should have an insurance professional review to ensure proper insurance classification.
Status A - Active record NCAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://eportal.nspa.nato.int/AC135Public/CageTool/cage-view/481X3
$MCET NAICS Code 541711 – Research and Development in Biotechnology
https://classcodes.com/lookup/naics-code-541711/
Definition of NAICS Code 541711: This U.S. industry comprises establishments primarily engaged in conducting biotechnology research and experimental development. Biotechnology research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology may result in development of new biotechnology processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.
You can also download your own copy of the complete 2017 NAICS Classification Manual. The NAICS Manual is updated every five years. The 2017 copy will be applicable until a new edition is produced in 2022.
Illustrative Examples of NAICS 541711
What are some examples of this code? The bulleted items below are illustrative examples of this classification.
Recombinant DNA research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Cloning research and experimental development laboratories
Protein engineering research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Cross Reference Guide for Code 541711
What codes are similar to this classification that might be a more applicable code? The cross-reference guide below displays the codes for other similar industries. Please review to find the most applicable classification.
Conducting research and experimental development in the physical, engineering, and life sciences (except biotechnology)–are classified in U.S. Industry NAICS 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology);
Providing veterinary testing services–are classified in Industry NAICS 541940, Veterinary Services; Providing physical, chemical, or other analytical testing services (except medical or veterinary), such as acoustics or vibration testing, calibration testing, electrical and electronic testing, geotechnical testing, mechanical testing, nondestructive testing, or thermal testing–are classified in Industry NAICS 541380, Testing Laboratories;
Manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic use)–are classified in U.S. Industry NAICS 325414, Biological Product (except Diagnostic)
Manufacturing; and Manufacturing uncompounded medicinal chemicals and their derivatives (i.e., enzyme proteins and antibiotics for pharmaceutical use)–are classified in U.S. Industry NAICS 325411, Medicinal and Botanical Manufacturing.
Other Index Entries for NAICS 541711
The North American Industry Classification System contains multiple index entries that are each descriptive of the same code. The bulleted list below shows all applicable index entries (Current and former) that are associated with this classification. These index entries further elaborate on the scope of applicable industries that have already been defined at the top of this page.
Biotechnology research and development laboratories or service in botany
Biotechnology research and development laboratories or services
Biotechnology research and development laboratories or services in agriculture
Biotechnology research and development laboratories or services in bacteriology
Biotechnology research and development laboratories or services in biology
Biotechnology research and development laboratories or services in chemical sciences
Biotechnology research and development laboratories or services in entomology
Biotechnology research and development laboratories or services in environmental science
Biotechnology research and development laboratories or services in food science
Biotechnology research and development laboratories or services in genetics
Biotechnology research and development laboratories or services in health sciences
Biotechnology research and development laboratories or services in industrial research
Biotechnology research and development laboratories or services in the medical sciences
Biotechnology research and development laboratories or services in the physical sciences
Biotechnology research and development laboratories or services in the veterinary sciences
Cloning research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Protein engineering research and experimental development laboratories
Recombinant DNA research and experimental development laboratories
Suggested Insurance Conversion Table for NAICS Code 541711
Looking for an insurance classification other than the North American Industry Classification System? If a company falls within the industry defined on this page, then the class codes mentioned below may be applicable. Please note that the bulleted cross-reference guide below is not authoritative. Users should have an insurance professional review to ensure proper insurance classification.
Status A - Active record NCAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://eportal.nspa.nato.int/AC135Public/CageTool/cage-view/481X3
$MCET NAICS Code 541711 – Research and Development in Biotechnology
https://classcodes.com/lookup/naics-code-541711/
Definition of NAICS Code 541711: This U.S. industry comprises establishments primarily engaged in conducting biotechnology research and experimental development. Biotechnology research and experimental development involves the study of the use of microorganisms and cellular and biomolecular processes to develop or alter living or non-living materials. This research and development in biotechnology may result in development of new biotechnology processes or in prototypes of new or genetically-altered products that may be reproduced, utilized, or implemented by various industries.
You can also download your own copy of the complete 2017 NAICS Classification Manual. The NAICS Manual is updated every five years. The 2017 copy will be applicable until a new edition is produced in 2022.
Illustrative Examples of NAICS 541711
What are some examples of this code? The bulleted items below are illustrative examples of this classification.
Recombinant DNA research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Cloning research and experimental development laboratories
Protein engineering research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Cross Reference Guide for Code 541711
What codes are similar to this classification that might be a more applicable code? The cross-reference guide below displays the codes for other similar industries. Please review to find the most applicable classification.
Conducting research and experimental development in the physical, engineering, and life sciences (except biotechnology)–are classified in U.S. Industry NAICS 541712, Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology);
Providing veterinary testing services–are classified in Industry NAICS 541940, Veterinary Services; Providing physical, chemical, or other analytical testing services (except medical or veterinary), such as acoustics or vibration testing, calibration testing, electrical and electronic testing, geotechnical testing, mechanical testing, nondestructive testing, or thermal testing–are classified in Industry NAICS 541380, Testing Laboratories;
Manufacturing vaccines, toxoids, blood fractions, and culture media of plant or animal origin (except diagnostic use)–are classified in U.S. Industry NAICS 325414, Biological Product (except Diagnostic)
Manufacturing; and Manufacturing uncompounded medicinal chemicals and their derivatives (i.e., enzyme proteins and antibiotics for pharmaceutical use)–are classified in U.S. Industry NAICS 325411, Medicinal and Botanical Manufacturing.
Other Index Entries for NAICS 541711
The North American Industry Classification System contains multiple index entries that are each descriptive of the same code. The bulleted list below shows all applicable index entries (Current and former) that are associated with this classification. These index entries further elaborate on the scope of applicable industries that have already been defined at the top of this page.
Biotechnology research and development laboratories or service in botany
Biotechnology research and development laboratories or services
Biotechnology research and development laboratories or services in agriculture
Biotechnology research and development laboratories or services in bacteriology
Biotechnology research and development laboratories or services in biology
Biotechnology research and development laboratories or services in chemical sciences
Biotechnology research and development laboratories or services in entomology
Biotechnology research and development laboratories or services in environmental science
Biotechnology research and development laboratories or services in food science
Biotechnology research and development laboratories or services in genetics
Biotechnology research and development laboratories or services in health sciences
Biotechnology research and development laboratories or services in industrial research
Biotechnology research and development laboratories or services in the medical sciences
Biotechnology research and development laboratories or services in the physical sciences
Biotechnology research and development laboratories or services in the veterinary sciences
Cloning research and experimental development laboratories
DNA technologies (e.g., microarrays) research and experimental development laboratories
Nanobiotechnologies research and experimental development laboratories
Nucleic acid chemistry research and experimental development laboratories
Protein engineering research and experimental development laboratories
Recombinant DNA research and experimental development laboratories
Suggested Insurance Conversion Table for NAICS Code 541711
Looking for an insurance classification other than the North American Industry Classification System? If a company falls within the industry defined on this page, then the class codes mentioned below may be applicable. Please note that the bulleted cross-reference guide below is not authoritative. Users should have an insurance professional review to ensure proper insurance classification.
Status A - Active record NCAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://eportal.nspa.nato.int/AC135Public/CageTool/cage-view/481X3
$MCET Multicell Technologies has two active programs! Commercial and Government Entity NCAGE481X3 and COMMERCIAL AND GOVERNMENT ENTITY PROGRAM CAGE481X3
NCAGE CODE 481X3: NCAGE Code Registration Status A - Active record
MULTICELL TECHNOLOGIES, INC. Last Updated 2020-02-26 04:18:07
https://cage.report/NCAGE/481X3
Status Active CAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://cage.dla.mil/Search/Details?id=894402
$MCET Multicell Technologies has two active programs! Commercial and Government Entity NCAGE481X3 and COMMERCIAL AND GOVERNMENT ENTITY PROGRAM CAGE481X3
NCAGE CODE 481X3: NCAGE Code Registration Status A - Active record
MULTICELL TECHNOLOGIES, INC. Last Updated 2020-02-26 04:18:07
https://cage.report/NCAGE/481X3
Status Active CAGE 481X3: MULTICELL TECHNOLOGIES, INC.
https://cage.dla.mil/Search/Details?id=894402
$MCET Amazing! Its going up! FAKEWALL is no longer present. $$$ BOOOOM UP $$$
$MCET Amazing! Its going up! FAKEWALL is no longer present. $$$ BOOOOM UP $$$
$MCET 0.001 +25.00% Volume: 60,900,015 >>> FAKEWALL <<< GOING UP WEEEE $$$$$$$$$$
$MCET 0.001 +25.00% Volume: 60,900,015 >>> FAKEWALL <<< GOING UP WEEEE $$$$$$$$$$
$IDGC Subsidiaries Noveda Technologies, Inc. KEY FACTS $$$$$$$$$$
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995172
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995318
$IDGC Subsidiaries Noveda Technologies, Inc. KEY FACTS $$$$$$$$$$
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995172
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160995318
$IDGC Absolutely Confirmed! For all! Please read the info!
Last quarter filings! 11/17/2019 Quarterly Report - Quarterly Report Q3 2019 Supplemental
>>>>> 5) Issuer’s Business, Products and Services <<<<<
https://backend.otcmarkets.com/otcapi/company/financial-report/234964/content
CERTIFICATE OF DOCUMENT FILED / Statement Curing Delinquency Page 1-4. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969871
Get a certificate of good standing
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969369
The content is confirmed! IoT 4.0 and Noveda Technologies!
https://www.otcmarkets.com/stock/IDGC/news/ID-Global-Corp-Announces-Corporate-Update-Management-Structure-after-Acquisition-by-Liberty-Capital-Group-of-San-Diego?id=228525
https://www.otcmarkets.com/stock/IDGC/news/IDGC-Completes-Strategic-Investment-In-Noveda-Technologies?id=233617
Liberty Capital Group. has the leadership position! Idglobal corporation subsidiaries is Farallon, inc., Prestige Liquids, LLC and Noveda Technologies, Inc.
Makes Idglobal also profit on Farallon, Inc.? Please review! They have a great many contracts.
https://govtribe.com/vendors/farallon-inc-dot-89wm4
PDF FORMAT!
Select Download FAR Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
Select Download FAR & DFARS Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
https://beta.sam.gov/entity/081494822?keywords=%22Farallon%20Inc.%22&sort=-relevance&index=&is_active=true&page=1&status=active
$IDGC Absolutely Confirmed! For all! Please read the info!
Last quarter filings! 11/17/2019 Quarterly Report - Quarterly Report Q3 2019 Supplemental
>>>>> 5) Issuer’s Business, Products and Services <<<<<
https://backend.otcmarkets.com/otcapi/company/financial-report/234964/content
CERTIFICATE OF DOCUMENT FILED / Statement Curing Delinquency Page 1-4. https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969871
Get a certificate of good standing
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=160969369
The content is confirmed! IoT 4.0 and Noveda Technologies!
https://www.otcmarkets.com/stock/IDGC/news/ID-Global-Corp-Announces-Corporate-Update-Management-Structure-after-Acquisition-by-Liberty-Capital-Group-of-San-Diego?id=228525
https://www.otcmarkets.com/stock/IDGC/news/IDGC-Completes-Strategic-Investment-In-Noveda-Technologies?id=233617
Liberty Capital Group. has the leadership position! Idglobal corporation subsidiaries is Farallon, inc., Prestige Liquids, LLC and Noveda Technologies, Inc.
Makes Idglobal also profit on Farallon, Inc.? Please review! They have a great many contracts.
https://govtribe.com/vendors/farallon-inc-dot-89wm4
PDF FORMAT!
Select Download FAR Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
Select Download FAR & DFARS Report to review the Representations and Certifications for FARALLON INC. <<<<<<<
https://beta.sam.gov/entity/081494822?keywords=%22Farallon%20Inc.%22&sort=-relevance&index=&is_active=true&page=1&status=active
Next Step hit up! Its coming! Market Makers confirm! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
Next Step hit up! Its coming! Market Makers confirm! https://investorshub.advfn.com/MultiCell-Technologies-MCET-2694/
$MCET .0009 +12.50% Volume: 54,141,127
$MCET .0009 +12.50% Volume: 54,141,127
$MCET Great Income per year! Look here! https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161288888
$MCET Great Income per year! Look here! https://investorshub.advfn.com/boards/read_msg.aspx?message_id=161288888
$MCET PLEASE READ! What is Multicell Technologies' stake with an average unit sales of 20,000 units and an average price of $ 631 dollars per year???
For example: 20,000 units * $631 dollars = $12,620,000 dollars per year.
$MCET PLEASE READ! What is Multicell Technologies' stake with an average unit sales of 20,000 units and an average price of $ 631 dollars per year???
For example: 20,000 units * $631 dollars = $12,620,000 dollars per year.